Jonathan Root Biography and Net Worth

Director of eFFECTOR Therapeutics

Jonathan Root spent nine years in clinical practice before joining USVP in 1995 as an Ewing Marion Kauffman Fellow in venture capital. He became a general partner in 1997. Before USVP, Dr. Root was on the faculty and clinical staff at The New York Hospital-Cornell Medical Center in New York City. There he was an assistant professor of neurology and director of the neurology-neurosurgery special care unit. He is board certified in neurology. Dr. Root is currently on the boards of USVP portfolio companies of Cleave Biosciences, eFFECTOR Therapeutics, Inari Medical, Omada Health, Ribon and Route 92 Medical. Dr. Root is a former board member for the National Venture Capital Association (NVCA). He holds an A.B. in economics from Dartmouth College, an M.D. from the University of Florida College of Medicine and an M.B.A. from Columbia University.

What is Jonathan D. Root's net worth?: The estimated net worth of Jonathan D. Root is at least $3.13 as of March 30th, 2021. Dr. Root owns 15,625 shares of eFFECTOR Therapeutics stock worth more than $3 as of December 22nd. This net worth estimate does not reflect any other assets that Dr. Root may own. Learn More about Jonathan D. Root's net worth.
How do I contact Jonathan D. Root?: The corporate mailing address for Dr. Root and other eFFECTOR Therapeutics executives is 200 CLARENDON STREET 51ST FLOOR, BOSTON MA, 02116. eFFECTOR Therapeutics can also be reached via phone at 858-925-8215 and via email at [email protected]. Learn More on Jonathan D. Root's contact information.
Has Jonathan D. Root been buying or selling shares of eFFECTOR Therapeutics?: Jonathan D. Root has not been actively trading shares of eFFECTOR Therapeutics during the last ninety days. Most recently, Jonathan D. Root sold 324 shares of the business's stock in a transaction on Thursday, December 2nd. The shares were sold at an average price of $142.00, for a transaction totalling $46,008.00. Learn More on Jonathan D. Root's trading history.
Who are eFFECTOR Therapeutics' active insiders?: eFFECTOR Therapeutics' insider roster includes Christopher Ehrlich (Director), and Jonathan Root (Director). Learn More on eFFECTOR Therapeutics' active insiders.

Jonathan D. Root Insider Trading History at eFFECTOR Therapeutics

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction
12/2/2021	Sell	324	$142.00	$46,008.00
11/30/2021	Sell	1,096	$163.25	$178,922.00
11/26/2021	Sell	201	$175.25	$35,225.25
11/24/2021	Sell	1,460	$184.00	$268,640.00
11/22/2021	Sell	1,047	$196.50	$205,735.50
11/19/2021	Sell	289	$203.00	$58,667.00
11/17/2021	Sell	409	$228.25	$93,354.25
11/15/2021	Sell	202	$245.25	$49,540.50
11/11/2021	Sell	480	$259.25	$124,440.00
11/9/2021	Sell	1,151	$275.00	$316,525.00

Jonathan D. Root Buying and Selling Activity at eFFECTOR Therapeutics

eFFECTOR Therapeutics Company Overview

eFFECTOR Therapeutics, Inc., a biopharmaceutical company, engages in the development of selective translation regulator inhibitors (STRIs) for the treatment of cancer. The company's lead product candidates comprise Tomivosertib, an oral small-molecule inhibitor of MNK that is in phase 2b clinical trial for the treatment of patients with metastatic non-small cell lung cancer; and Zotatifin, a small molecule inhibitor of eukaryotic initiation factor 4A (eIF4E), which is in Phase 1/2 clinical trial to treat patients with solid tumors, as well as completed Phase 2a open-label expansion cohort in combination with fulvestrant and abemaciclib to treat patients with ER+ breast cancer. The company has a research collaboration and license agreement with Pfizer Inc. to research and develop small molecules that target eIF4E. eFFECTOR Therapeutics, Inc. was incorporated in 2012 and is headquartered in Solana Beach, California.

Today's Range

Now: $0.00

$0.00

50 Day Range

MA: N/A

2 Week Range

Now: $0.00

$0.00

$17.75

Volume

4,753 shs

Average Volume

278,163 shs

Market Capitalization

$940.80

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.61

The #1 Coin for November 2024

From Crypto 101 Media | Ad

You can get access to the report by clicking here now…